Key factors influencing dose selection include: Treatment goals : Whether the primary aim is glycaemic control, weight reduction, or cardiovascular risk reduction Baseline HbA1c and blood glucose levels : Higher values may eventually require higher maintenance doses Body weight and BMI : Particularly relevant for weight management indications Renal function : Most GLP-1 medications (semaglutide, liraglutide, dulaglutide) do not require dose adjustment for kidney impairment, but exenatide and lixisenatide should be used with caution or avoided in severe renal impairment Concurrent medications : Especially other glucose-lowering agents that might increase hypoglycaemia risk Previous medication tolerance : History of gastrointestinal sensitivity influences titration speed Cardiovascular history : Some GLP-1 medications have proven cardiovascular benefits at specific doses Diabetic retinopathy status : Rapid improvement in blood glucose can temporarily worsen retinopathy, particularly with semaglutide [22] [23] Your doctor will typically schedule regular follow-up appointments during the initial months of treatment

American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease - 2025 Update Endocr Pract
Username or email Reset password
Key Facts Scientists in Finland and Sweden on Wednesday published the results of a study using 17 years of data that observed more than 220,000 people who were diagnosed with alcohol use disorder and either had obesity or Type 2 diabetes, conditions most commonly treated by glucagon-like peptide-1 receptor (GLP-1) medications
The Core Program focuses on nutrition, activity, and habit change without medication
In research, GHK-Cu supports collagen production, tissue regeneration, hair follicle health, and skin elasticity